Fulcrum Therapeutics Business Summary

Fulcrum Therapeutics, Inc. (FULC) is a clinical-stage biopharmaceutical company that generates revenue primarily through strategic research collaborations, licensing agreements, and milestone payments, notably evidenced by its $80 million upfront collaboration with Sanofi. The company operates through a single business segment focused on the discovery and development of small molecules that modulate gene expression to treat genetically defined rare diseases. Its proprietary product engine, FulcrumSeek, identifies drug targets by mapping the gene regulatory network, with primary clinical focus on pociredir (FTX-6058) for sickle cell disease and beta-thalassemia following the late-stage setbacks of its FSHD candidate, losmapimod. Fulcrum competes directly with gene therapy and RNA-based firms such as bluebird bio, Alnylam Pharmaceuticals, Intellia Therapeutics, and Sangamo Therapeutics, positioning itself as a specialist in oral small-molecule epigenetic modulation rather than complex genetic engineering. The company is led by President and CEO Alex C. Sapir, an industry veteran who previously served as CEO of ReViral (acquired by Pfizer) and Dova Pharmaceuticals. The executive team includes CFO Alan Musso, also formerly of ReViral, and Chief Scientific Officer Jeff Jacobs, Ph.D., who brings over 25 years of drug discovery experience from Goldfinch Bio and AstraZeneca. Fulcrum was founded by a distinguished group of academic pioneers in epigenetics and genomics, including Bradley Bernstein, Michael Green, Rudolf Jaenisch, Tsun-Huei Lee, and Danny Reinberg. The company maintains a robust institutional investor base, with significant backing from RA Capital Management, BlackRock, and The Vanguard Group, while its board is chaired by Kathryn Haviland, the former CEO of Spruce Biosciences.